Amdipharm Mercury (‘AMCo’ or ‘the Group’) today announces that it has completed the acquisition of Abcur AB (‘Abcur’ or ‘the company’), a privately owned specialty pharmaceutical business, headquartered in Sweden.
Abcur is a specialty pharmaceutical business with a focus on the development, registration and marketing of a wide range of specialised prescription and non-prescription products within the Nordic markets for a number of therapeutic indications including addiction, intensive care, pain management and anaesthesia. Roger Tapper, a founder of Abcur, has run the company since its initiation in 2006 and along with his management team will be joining AMCo. The business has operations in Sweden, Finland, Norway, Denmark and Iceland. AMCo has already built a strong commercial relationship with the company as Abcur has been acting as a distributor for a number of AMCo’s products including Diamox, a treatment for glaucoma.
The acquisition of Abcur reinforces AMCo’s growth strategy to create a single and consolidated, international specialty pharmaceutical business through both organic growth and acquisition.
Commenting on this transaction, John Beighton, Chief Executive of AMCo, said:
“We are delighted to have completed this transaction. Abcur has a strong market position across the Nordic region and we already know the business well. It is extremely well run and we believe will benefit enormously from being part of a larger international group such as AMCo.
“This acquisition further demonstrates AMCo’s ability to increase its presence across Europe, as well as acquire businesses or products which will enable us to expand our business globally through the sale of additional products into international markets.”